FDA Gives Clearance to In Vivo Gene-Editing Therapy for AATD The FDA has approved the Investigational New Drug application for YOLT-202, an in vivo gene-editing therapy for AATD.

The @fda.gov has approved the Investigational New Drug (#IND) application for YOLT-202, an in vivo gene-editing therapy for alpha-1 antitrypsin deficiency (#AATD), according to a recent press release.

Read more: https://bit.ly/4draiFV

#RareDisease #YOLT202 #GeneEditingTherapy #Alpha1

#TIME names five #IndianAmerican health leaders in #TIME100Health for shaping #globalhealthcare in #AIEnabledCare, personalized #GeneEditingTherapy, #OpioidSurveillance and harm reduction, #CancerScreeningResearch, and #OncologyInnovation.

https://ow.ly/6UPA50YezQX

World's first patient treated with personalized CRISPR gene editing therapy – BioNews Central Landmark study showcases the power of personalized CRISPR gene editing therapy to treat a patient with rare metabolic disease. ...

Landmark study showcases the power of personalized #CRISPR #GeneEditingTherapy to treat a patient with rare #MetabolicDisease.
#GeneEditing #PersonalizedMedicine

NHS to offer 'groundbreaking' sickle cell gene therapy The gene therapy Casgevy, which will now be offered to some patients in England, could help people live disease-free, experts say.

#haematology #Sicklecelldisease #sicklecellgenetherapy #genetherapy #geneeditingtherapy #Casgevy #Exacel @vertexpharma.bsky.social #NHS #haemoglobin #clinicaltrials #functionalcure @AmandaPritchard #geneeditingtool #Crispr #editedstemcells #NHSEngland #clinicaltrials
www.bbc.co.uk/news/article...